News | July 29, 2025
Piramal Pharma reports Q1 FY26 consolidated loss at Rs. 81.70 Cr
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
Sigachi Industries has reported total income of Rs. 132.18 crores during the period ended June 30, 2025
Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
_256_384.jpg)
Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Subscribe To Our Newsletter & Stay Updated
